Bank of Montreal
HRTX icon

Bank of Montreal’s Heron Therapeutics HRTX Stock Holding History

Bank of Montreal’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,495
Closed -$19.5K – 3704
2025
Q3 		$19.5K Hold
15,495
– – ﹤0.01% 3287
2025
Q2 		$32.1K Sell
15,495
-10,606
-41% -$21.7K ﹤0.01% 3222
2025
Q1 		$57.4K Buy
+26,101
New +$50.7K ﹤0.01% 3043
2024
Q4 		– Sell
-25,194
Closed -$50.1K – 3719
2024
Q3 		$50.1K Buy
+25,194
New +$60.2K ﹤0.01% 3416
2022
Q3 		– Sell
-56,680
Closed -$192 – 4214
2022
Q2 		$192 Sell
56,680
-43,920
-44% -$176K ﹤0.01% 3286
2022
Q1 		$574K Sell
100,600
-61,530
-38% -$450K ﹤0.01% 2734
2021
Q4 		$1.51M Sell
162,130
-2,040
-1% -$20.8K ﹤0.01% 1734
2021
Q3 		$1.88M Sell
164,170
-185,939
-53% -$2.26M ﹤0.01% 2114
2021
Q2 		$5.56M Buy
350,109
+347,025
+11,252% +$5.52M ﹤0.01% 1556
2021
Q1 		$53K Sell
3,084
-11,094
-78% -$198K ﹤0.01% 3666
2020
Q4 		$274K Buy
14,178
+8,207
+137% +$143K ﹤0.01% 3045
2020
Q3 		$87K Sell
5,971
-3,129
-34% -$48.8K ﹤0.01% 3155
2020
Q2 		$142K Buy
9,100
+7,063
+347% +$116K ﹤0.01% 2905
2020
Q1 		$24K Sell
2,037
-12,784
-86% -$240K ﹤0.01% 3177
2019
Q4 		$347K Sell
14,821
-15,758
-52% -$349K ﹤0.01% 2864
2019
Q3 		$566K Buy
30,579
+22,379
+273% +$412K ﹤0.01% 2342
2019
Q2 		$153K Buy
8,200
+5,815
+244% +$116K ﹤0.01% 3076
2019
Q1 		$59K Sell
2,385
-48,647
-95% -$1.27M ﹤0.01% 3276
2018
Q4 		$1.32M Buy
51,032
+46,384
+998% +$1.28M ﹤0.01% 1750
2018
Q3 		$147K Sell
4,648
-580
-11% -$21.6K ﹤0.01% 2918
2018
Q2 		$203K Buy
5,228
+527
+11% +$16.8K ﹤0.01% 2747
2018
Q1 		$130K Buy
4,701
+750
+19% +$17K ﹤0.01% 2852
2017
Q4 		$71K Sell
3,951
-149
-4% -$2.43K ﹤0.01% 3134
2017
Q3 		$66K Buy
4,100
+704
+21% +$11K ﹤0.01% 3127
2017
Q2 		$47K Buy
3,396
+500
+17% +$7.24K ﹤0.01% 3239
2017
Q1 		$43K Sell
2,896
-7,466
-72% -$103K ﹤0.01% 3137
2016
Q4 		$160K Sell
10,362
-1,020
-9% -$16K ﹤0.01% 2591
2016
Q3 		$196K Buy
11,382
+10,973
+2,683% +$204K ﹤0.01% 2472
2016
Q2 		$7K Hold
409
– – ﹤0.01% 3662
2016
Q1 		$8K Sell
409
-112,311
-100% -$2.22M ﹤0.01% 3674
2015
Q4 		$3.01M Buy
+112,720
New +$3.01M ﹤0.01% 1211

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Bank of Montreal's HRTX Position: Q4 2025 in Review

Bank of Montreal sold out of Heron Therapeutics (HRTX) in Q4 2025, closing a stake of 15,495 shares — an estimated $19.5K sold.

Bank of Montreal first reported a position in HRTX in Q4 2015 and held it in 31 quarters. The position peaked at $5.56M in Q2 2021. 170 funds tracked by Wall St. Rank hold HRTX as of Q4 2025.

  • Bank of Montreal reported no remaining Heron Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bank of Montreal sold 15,495 Heron Therapeutics shares in Q4 2025, an estimated $19.5K.
  • Bank of Montreal first reported a position in Heron Therapeutics in Q4 2015 and held it in 31 quarters.
  • Bank of Montreal's Heron Therapeutics position peaked at $5.56M in Q2 2021.
  • 170 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2025.

Based on Bank of Montreal's 13F filing for Q4 2025, filed 12 Feb 2026.